Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP (POINT)
This study has been terminated.
( Study Terminated.priority changes in product development. )
Study NCT01225276   Information provided by Octapharma

First Received on October 6, 2010.   Last Updated on October 10, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Polyradiculoneuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Neuromuscular Diseases
Peripheral Nervous System Diseases
Polyneuropathies
Interventions listed in this trial
NewGam 10%
Sponsors listed in this trial
Octapharma


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services